Voyageur Pharmaceuticals Ltd. is advancing its strategy to establish a secure, vertically integrated supply chain for barium and iodine contrast media drugs used in medical imaging. The company aims to address supply chain vulnerabilities in a diagnostic imaging market projected to grow from US$6.77 billion in 2024 to US$13.86 billion by 2033, according to Research Contrast. With barite classified as a critical mineral by the U.S. Geological Survey, Voyageur's approach involves controlling the entire value chain from mineral discovery to finished product manufacturing.
The company is currently completing two bankable feasibility studies that form the foundation of this strategy. The Voyageur Radiology Iodine & Barium Drug Manufacturing Project and the Bayer Iodine Project represent foundational steps toward establishing a resilient, North American–based supply chain capable of supporting growing global demand for diagnostic imaging pharmaceuticals.
Voyageur's barium strategy centers on the Frances Creek project, which hosts an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical grade barium sulfate. Recent testing confirms the barite purity exceeds Pharmaceutical Grade requirements, with an average grade of 98.8% BaSO4. The company has completed product development initiatives for five Health Canada approved barium products with Alberta Veterinary Laboratories, a GMP pharmaceutical manufacturer, and has generated approximately C$32,000 in initial contrast product sales, establishing commercial validation. A preliminary economic assessment valued the FC barium contrast project with a net present value of $344 million, as detailed in a news release dated January 11, 2022.
Regulatory pathways for barium and iodine contrast media are expected to follow an 18 to 24-month FDA review and approval process, potentially enabling U.S. barium market entry as soon as mid-2027 to late 2027. Voyageur has completed the first drafts of all barium FDA submission documents and formally commenced the approval process in February 2026 via the 505(b)(2) regulatory pathway. The company plans to advance a generic iodine FDA license in the second half of 2026, further strengthening its pharmaceutical portfolio.
For its iodine strategy, Voyageur is independently advancing a prefeasibility study integrating the Mueller iodine extraction process with the Streamline iodine drug manufacturing platform. The project leverages iodine-rich brine sourced from oil and gas operations and water disposal companies in the United States, targeting 35 million doses per year of iodine contrast drug production. The combined processes are expected to significantly lower manufacturing costs for iodine drugs.
The Bayer Iodine Project represents another key component of Voyageur's strategy, with US$2.35 million in funding focused on completing a BFS. Subject to successful completion, Bayer and Voyageur may consider advancing the project into a second phase under an offtake-linked production financing arrangement. This collaboration, which began with the signing of an LOI with Bayer on December 20, 2024, represents an important step in Voyageur's mission to become the first domestic producer of iodine contrast in the United States.
Voyageur is engaging with a global engineering company to complete the final two BFS studies. Upon completion, the company will have finalized the economics and plant design to vertically produce iodine and barium contrast media drugs, positioning itself to become the only vertically integrated radiology drug company in the marketplace. The company is actively reviewing financial options to fund future capital expenditures, targeting construction to commence in 2027.
These developments have significant implications for healthcare infrastructure and supply chain security. By establishing a North American-based supply chain for critical contrast media drugs, Voyageur aims to reduce dependency on international suppliers and create more resilient healthcare systems. The vertical integration strategy could potentially lower production costs while ensuring consistent quality and supply availability for healthcare providers facing growing diagnostic imaging demands.
